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Background-—Gadolinium enhancement on high-resolution magnetic resonance imaging (MRI) has been proposed as a marker of
inﬂammation and instability in intracranial atherosclerotic plaque. We performed a systematic review and meta-analysis to
summarize the association between intracranial atherosclerotic plaque enhancement and acute ischemic stroke.
Methods and Results-—We searched the medical literature to identify studies of patients undergoing intracranial vessel wall MRI
for evaluation of intracranial atherosclerotic plaque. We recorded study data and assessed study quality, with disagreements in
data extraction resolved by a third reader. A random-effects odds ratio was used to assess whether, in any given patient, cerebral
infarction was more likely in the vascular territory supplied by an artery with MRI-detected plaque enhancement as compared to
territory supplied by an artery without enhancement. We calculated between-study heterogeneity using the Cochrane Q test and
publication bias using the Begg-Mazumdar test. Eight articles published between 2011 and 2015 met inclusion criteria. These
studies provided information about plaque enhancement characteristics from 295 arteries in 330 patients. We found a signiﬁcant
positive relationship between MRI enhancement and cerebral infarction in the same vascular territory, with a random effects odds
ratio of 10.8 (95% CI 4.1–28.1, P<0.001). No signiﬁcant heterogeneity (Q=11.08, P=0.14) or publication bias (P=0.80) was
present.
Conclusions-—Intracranial plaque enhancement on high-resolution vessel wall MRI is strongly associated with ischemic stroke.
Evaluation for plaque enhancement on MRI may be a useful test to improve diagnostic yield in patients with ischemic strokes of
undetermined etiology. ( J Am Heart Assoc. 2016;5:e003816 doi: 10.1161/JAHA.116.003816)
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I ntracranial atherosclerosis is one of the most commoncauses of ischemic stroke worldwide1,2 and is associated
with a high rate of recurrence.3 The most commonly used
imaging techniques to assess intracranial atherosclerosis,
such as computed tomographic angiography or magnetic
resonance angiography, provide information on the degree of
narrowing of the vascular lumen. Most classiﬁcation schemes
for ischemic stroke etiology require plaque to cause ≥50%
stenosis for a given stroke to be attributable to large-artery
atherosclerosis.4 However, magnetic resonance imaging (MRI)
studies of the extracranial carotid arteries suggest that many
atherosclerotic plaques have high-risk features despite the
absence of signiﬁcant luminal narrowing.5,6 It is unknown to
what extent similar nonstenosing intracranial atherosclerotic
plaque might be responsible for a proportion of the approx-
imately 1 in 3 ischemic strokes for which no clear etiology can
be determined.7
Recent investigations have begun to address this problem
by leveraging high-resolution, multiplanar MRI to detect high-
risk abnormalities of the intracranial vessel walls. Previous
studies in both the coronary and extracranial carotid arteries
have shown that abnormal plaque enhancement after the
administration of gadolinium contrast agent is a marker of
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inﬂammation, neovascularity, and plaque instability.8,9 For
this reason, plaque enhancement has been recently studied
as a potential high-risk plaque feature in the intracranial
circulation (Figure 1). Plaque enhancement is a particularly
attractive MRI biomarker because it can be rapidly detected,
qualitatively assessed, and does not require signiﬁcant image
postprocessing to analyze. While research to date on the
detection of nonstenosing intracranial atherosclerotic lesions
based on enhancement characteristics has been promising,
individual studies have been small, making it difﬁcult to draw
ﬁrm conclusions about this emerging technique. We therefore
performed a systematic review and meta-analysis to evaluate
the association between abnormal plaque enhancement on
high-resolution MRI and acute ischemic stroke.
Methods
We performed this study following the Meta-Analysis of
Observational Studies in Epidemiology (MOOSE) group guide-
lines10 and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses statement.11 Because this was an
analysis of previously published data, this study did not
undergo or require Institutional Review Board approval.
Data Sources and Searches
Two research librarians performed comprehensive searches of
Ovid MEDLINE, Ovid Embase, and the Cochrane Library from
database inception to December 21, 2015. We ﬁrst con-
ducted our search in Ovid MEDLINE. We then adapted
headings and keywords for other databases and identiﬁed
additional records by employing the “Cited by” and “View
references” features in Scopus (see Data S1 for search
methodology details).
Study Selection
We included studies evaluating the association of abnormal
plaque enhancement on vessel wall MRI with recent ischemic
stroke. Speciﬁc inclusion criteria were as follows: (1) studies
of patients with acute cerebral infarction; (2) studies of
patients who underwent MRI of the intracranial vessels with
assessment of plaque signal abnormalities within 30 days of
Figure 1. Magnetic resonance images showing an enhancing atherosclerotic plaque in the right middle
cerebral artery in a symptomatic patient who had suffered a recent right cerebral hemispheric acute
ischemic stroke. A mixture of acute and chronic infarction involving the right periventricular and frontal
subcortical regions is seen in the diffusion-weighted image (DWI); the plaque is shown by an arrow in the
time-of-ﬂight (TOF) image, and a cross section at the most stenotic site is shown in T2, T1, and contrast-
enhanced (CE) T1 images (red asterisks: lumen).
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the ischemic stroke; (3) speciﬁc assessment of the presence
or absence of plaque postgadolinium enhancement; (4)
reporting of the prevalence of plaque enhancement in the
arteries directly supplying blood to the territory of the
infarction compared to the prevalence of enhancement in
an unrelated vascular territory (such as contralateral hemi-
sphere for an anterior circulation infarction); and (5) studies
with ≥10 subjects to avoid the inclusion of case reports or
small case series. We only included peer-reviewed journal
articles rather than conference proceedings or abstracts. We
did this to ensure that the studies included in our analysis
provided sufﬁcient information to allow for the collection of
patient characteristics, MRI study protocols, and MRI test
results in a fashion that would allow us to perform a detailed
systematic review and meta-analysis. In otherwise eligible
studies, we excluded patients with infarctions that were likely
secondary to nonatherosclerotic etiologies such as vasculitis
or reversible cerebral vasoconstriction syndrome. We also did
not include patient data for chronic ischemic strokes or
transient ischemic attacks. If based on review of study
inclusion dates, authors appeared to have published data from
a single cohort or medical center more than once, the single
article with the largest sample size was included to minimize
analysis of duplicate or overlapping samples. When necessary
we attempted to contact the corresponding author for
additional details to clarify our data extraction.
Data Extraction and Quality Assessment
A single investigator read the title and abstract of all
references produced by our database search. After prelimi-
nary articles were shortlisted as potentially eligible, 2 readers
read the articles in their entirety to determine eligibility, with
disagreements resolved by consensus. We extracted data in
duplicate using a prespeciﬁed data collection template. A
third tie-breaking reader resolved disagreements in data
extraction. We extracted the following study characteristics:
ﬁrst author; study design (prospective or not); major study
inclusion criteria; country of the study; total number of
subjects; basic study demographics and the prevalence of
stroke risk factors in the studied populations, including age,
sex, hypertension, diabetes, atrial ﬁbrillation, coronary artery
disease, hyperlipidemia, and smoking history; deﬁnitions of
ischemic stroke and delineation of vascular territories; and
speciﬁc MRI techniques employed, including deﬁnitions of
abnormal plaque enhancement. We classiﬁed strokes in each
of 2 groups: (1) all strokes in the vascular territory of an artery
with plaque enhancement and (2) all strokes in the vascular
territory of arteries free of plaque enhancement. This allowed
for the calculation of a pooled odds ratio (OR) comparing the
prevalence of infarction in tissue supplied by an artery with
enhancing plaque versus tissue supplied by unaffected
arteries, with each patient serving as his or her own control;
an OR >1 would indicate an association between plaque
enhancement and infarction.
We adapted risk of bias assessments in previously
published meta-analyses of MRI biomarkers of stroke risk12,13
and generated 8 speciﬁc questions to evaluate for potential
selection, detection, reporting, and confounding bias (see
Data S1). Two readers assessed for risks of bias using this
questionnaire, with disagreements in assessment resolved by
a third tie-breaking evaluator.
Data Synthesis and Analysis
We performed a meta-analysis of the individual study ORs (ie,
odds of the strength of association between enhancement
and ipsilateral infarction) using R package “meta” (version
4.3-2). We also performed a sensitivity analysis limited to
prospective studies. We pooled ORs using a random-effects
(DerSimonian-Laird) model and generated a forest plot to
display the individual study ORs and the pooled ORs. We used
a random-effects model because we conservatively assumed
that individual studies did not have the same effect size given
the high possibility of between-study heterogeneity in terms
of sample size, subject characteristics, and imaging methods.
The random-effects analysis allows for more variability in the
individual study OR estimates when generating the pooled OR.
A continuity correction of 0.5 was applied to studies with zero
cell frequencies. To assess the combinability of the ORs, we
calculated the P-value from the Cochrane Q statistical
heterogeneity test. For each meta-analysis, the presence of
publication bias was evaluated through a funnel plot. The
Begg-Mazumdar rank-correlation test was used to statistically
assess the presence of publication bias. All P<0.05 were
considered statistically signiﬁcant.
Results
Study Selection and Characteristics
We screened a total of 4437 titles and abstracts from which
we identiﬁed 8 articles14–21 that met all inclusion criteria for
the systematic review. Study selection steps are summarized
in Figure 2. In total, the 8 studies included a combined 330
individual subjects in whom data from 295 atherosclerotic
plaques provided data eligible for meta-analysis. Of the 8
articles meeting inclusion criteria (Table 1), 514,18–21 were
prospective cross-sectional studies and 315–17 were retro-
spective cross-sectional studies. Three studies were con-
ducted in China,19–21 2 in the United States,17,18 and 1 each
in Canada,16 the Netherlands,14 and South Korea.15 A
preponderance of men were studied in 7 of the 8 included
studies, with the range of percent of men in each study
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ranging from 46.9% to 88.9%. All studies had a mean age
above 50 years (range 54.6–68.7 years). There were differ-
ences in the degree of intracranial luminal stenosis measure-
ments required for patients to be included in the individual
studies, with some studies17,18,20 requiring ≥50% or ≥70%
stenosis while others focused on patients without signiﬁcant
stenosis (ie, <50%).19,21 Though some studies included
patients with transient ischemic attacks or nonacute ischemic
strokes, all included studies provided adequate information to
collect MRI enhancement data on the subset of relevant
patients with acute ischemic stroke occurring within 30 days
of imaging.
Deﬁnitions of Abnormal Plaque Enhancement and
Delineation of Vascular Territories
Evaluation for abnormal plaque enhancement on all studies
occurred on postcontrast T1-weighted sequences, with most
studies using a high-resolution technique capable of submil-
limeter resolution (Table 2). Six studies15,16,18–21 were per-
formed on 3.0-T MRI scanners, 114 on a 7.0-T scanner, and
117 on a 1.5-T scanner. All but 1 study16 involved more than 1
reader evaluating vessel wall MRI for abnormal vessel wall
enhancement. Though there were some between-study
differences in the deﬁnition of abnormal plaque enhancement,
abnormal plaque was most commonly deﬁned as enhance-
ment judged to be the same or greater than the degree of
physiologic enhancement present in the adjacent pituitary
gland. Similarly, though speciﬁc deﬁnitions varied, all studies
explicitly differentiated acute neuroimaging-conﬁrmed infarc-
tions occurring in the vascular territory of an artery with
enhancing plaque, versus infarctions occurring in the vascular
territory of an artery without enhancing plaque. All studies
evaluated for enhancement in either the intracranial internal
carotid artery or the middle cerebral artery.
Association Between Plaque Enhancement and
Cerebral Infarction
We were able to obtain sufﬁcient raw data to calculate a
pooled OR expressing the strength of association between
MRI enhancement and cerebral infarction in all of our included
Figure 2. Study selection ﬂow diagram.
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8 studies (Table 3). In this analysis, information about plaque
enhancement characteristics was available from 295
atherosclerotic lesions, 143 of which supplied a vascular
territory containing an acute infarction and 152 of which
supplied an infarct-free vascular territory. We found a
signiﬁcant association between MRI enhancement of an
artery and stroke within the vascular territory of that same
artery, with a random effects OR of 10.8 (95% CI 4.1–28.1,
P<0.001, Figure 3). These results were robust to a sensitivity
analysis excluding the 2 retrospective studies (OR 8.4, 95% CI
3.1–22.8, P<0.001). There was neither statistically signiﬁcant
heterogeneity (Q=11.08, P=0.14) nor signiﬁcant publication
bias (Begg-Mazumdar test for publication bias P=0.80,
Figure 4) present in this analysis.
Assessment of the Quality of the Included
Studies
The results from the quality assessment questionnaire are
shown in Table 4. All studies provided detailed description of
study inclusion/exclusion criteria and 6 of 8 studies14,17–21
were prospectively conducted. Seven15–21 of 8 studies had as
Table 3. MRI Test Results
Study
Number
Study First Author
and Year
Total Number of Suspected
Culprit Plaques Causing
Downstream Ischemic
Stroke Only Imaged in
Acute Phase
Number of Enhancing
Suspected Culprit Plaques
Causing Downstream
Ischemic Stroke Imaged in
Acute Phase
Total Number of
Non-Culprit Plaques
Number of Enhancing
Non-Culprit Plaques
1 van der Kolk 201114 5 3 12 1
2 Kim 201215 21 14* 8† 0
3 Skarpathiotakis 2013‡16 13 13 2 0
4 Vakil 201317 7 4 3 0
5 Qiao 201418 21 19 45 10
6 Teng 2015§19 82 41 27 7
7 Xu 201520 15 12 17 4
8 Zou 2015k21 12 11 5 4
MRI indicates magnetic resonance imaging.
*Data obtained via direct author correspondence.
†The nonculprit group had no evidence of any signiﬁcant middle cerebral artery (MCA) plaque (and no abnormal wall or plaque enhancement).
‡Three patients had multiple plaques in the same territory for which individual plaque-level data were not available.
§The nonculprit group included plaques in separately recruited asymptomatic subjects.
kAuthors provided enhancement data speciﬁcally for superiorly situated MCA plaques ipsilateral and contralateral to infarctions.
Figure 3. Forest plot of the association between magnetic resonance imaging–determined plaque contrast enhancement (CE) and acute
ischemic stroke. The meta-analysis was calculated using a random-effects model, with the pooled odds ratio (OR) shown in the forest plot. Each
square represents the point estimate of any given study’s effect size. The size of the squares is proportional to the inverse of the variance of the
estimate, while the horizontal lines represent each study’s 95% CIs. The diamond represents the pooled estimate with the width of the diamond
representing the pooled 95% CI.
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a primary objective to determine whether enhancement was
associated with acute ischemic change in the brain. Similarly,
715–21 of 8 studies had investigators blinded to the location of
infarction during vessel wall enhancement detection and
utilized more than 1 reader to evaluate for plaque enhance-
ment, though only 2 studies17,18 reported interreader repro-
ducibility measures. The classiﬁcation of strokes as occurring
in the territory of enhancing arterial plaque versus in territory
without enhancing plaque occurred by an adjudicated panel of
more than 1 investigator in only 1 study.18 Finally, no studies
consistently matched enhancing plaques leading to down-
stream infarction versus plaque in infarct-free territory in
regard to stenosis severity.
Discussion
Increasing the diagnostic conﬁdence that a speciﬁc
atherosclerotic lesion is the cause of a patient’s ischemic
stroke is important because it can guide optimal secondary
stroke prevention measures. By characterizing plaque char-
acteristics beyond luminal stenosis, MRI of the vessel wall is a
promising technique to detect speciﬁc plaque features
associated with acute ischemic infarction. In this systematic
review and meta-analysis we studied nearly 300 plaques
imaged with vessel wall MRI pooled together from 8 individual
studies, and focused on 1 such high-risk atherosclerotic
plaque feature, enhancement after gadolinium administration.
We found that plaque enhancement is strongly associated
with downstream acute infarction. Infarction was 10 times
more likely in tissue supplied by an enhancing artery than in
tissue supplied by nonenhancing arteries.
The mechanisms of plaque enhancement in vulnerable
intracranial atherosclerotic plaques are likely complex and
multifactorial. Much of our understanding of the pathophysi-
ology of gadolinium enhancement in the cerebral arterial vessel
wall arises from literature on the extracranial carotid arteries
where endarterectomy specimens are more readily accessible
for pathological correlation. In these studies, carotid plaque
gadolinium enhancement has been shown to spatially correlate
with histological markers of vessel wall neovascularization and
inﬂammation, both well-known markers of unstable atheroscle-
rotic plaque.9 Enhancement detectable on MRI may be related
to endothelial dysfunction present in the diseased intraplaque
microvasculature of atherosclerotic vessels.22 Such compro-
mised microvascular endothelium likely results in the vascular
leakage needed for gadolinium to accumulate in the perivas-
cular spaces and become detectable on T1-weighted MRI
sequences. However, it is important to note that unlike the
extracranial carotid arteries, most intracranial vessels do not
have a vasa vasorum, though there is evidence that arte-
riosclerosis can promote the development of vasa vasorum in
the proximal intracranial vasculature.23,24 As a result, though it
is likely that a leaky endothelial barrier due to inﬂammation is
responsible for the gadolinium enhancement seen in the
studies included in this meta-analysis, the speciﬁc contribution
of vasa vasorum to this enhancement requires further
histopathological evaluation.
Understanding the time course of intracranial plaque
enhancement after an acute ischemic event would help
optimize the timing and diagnostic yield of intracranial vessel
wall MRI in patients presenting with ischemic stroke. One
study16 in this meta-analysis also focused on the longitudinal
pattern of plaque enhancement after ischemic stroke and
found that the strength of enhancement was its highest in the
acute stroke phase (within 4 weeks), and that enhancement
steadily decreased as the infarct became chronic in age (after
12 weeks). Though there are limited data suggesting the
plaque enhancement may also predict future stroke recur-
rence,25 further work is necessary to more fully elucidate the
temporal relationships between MRI plaque enhancement,
prior ischemic stroke, and future ischemic stroke risk.
We focused our analysis on gadolinium enhancement
rather than other speciﬁc proposed high-risk plaque elements
such as intraplaque hemorrhage, ﬁbrous cap abnormalities, or
lipid-rich necrotic core because of the paucity of studies
Figure 4. Funnel plot to evaluate for publication bias. Individual
study effect sizes expressed as odds ratios are shown on the x-
axis and each study’s standard error is shown on the y-axis.
Larger and more precise studies are plotted at the top, near the
combined (pooled) odds ratio, whereas smaller and less precise
studies will show a wider distribution below. If there is no
publication bias, the studies would be expected to be symmet-
rically distributed on both sides of the pooled odds ratio line. In
the case of publication bias, the funnel plot may be asymmetrical,
since the absence of studies would distort the distribution on the
scatter plot.
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evaluating these speciﬁc elements in the intracranial circula-
tion. The lack of studies evaluating these features may be
because these speciﬁc elements are much more difﬁcult to
detect in the intracranial vasculature due to its smaller size
and deeper location compared to the extracranial carotid
arteries where they have been more well characterized,
including in studies with histopathological conﬁrmation.13
Similarly, though some recent studies have proposed quan-
titative biomarkers of high-risk plaque such as arterial
remodeling ratios or surface area measurements of
plaque,19–21 such measures require intensive and precise
measurements of plaque that may be challenging to imple-
ment into clinical practice. Evaluating for the presence or
absence of gadolinium enhancement, on the other hand, may
offer a relatively simple and rapid method of detecting high-
risk plaque that could be used routinely in MRI examinations
of patients presenting with acute ischemic stroke.
Our study has revealed some limitations about the
existing literature evaluating the relationship between plaque
MRI enhancement and acute ischemic stroke. First, though
there was general agreement on the MRI features of plaque
enhancement, including a greater degree of signal intensity
than normal vessel wall enhancement, the reference stan-
dard by which abnormal enhancement is determined varied
by study. The pituitary gland may offer an easily identiﬁable
reference standard by which plaque enhancement can be
subjectively assessed since it is located in close proximity to
the circle of Willis vessels, thereby ensuring its presence in
the MRI ﬁeld-of-view. Indeed, good interobserver consistency
was shown using the pituitary gland as a reference to judge
enhancement in the 1 study18 reporting interpretive repro-
ducibility. Future studies will be strengthened if authors
report interreader reproducibility measures more consistently
in their interpretation of intracranial vessel wall MRI studies.
Second, we found that studies did not routinely control for or
match enhancing plaques leading to downstream infarction
versus plaque in infarct-free territory in regard to stenosis
severity. Indeed, stenosis severity was not systematically
reported in all included studies. This makes it unclear to
what extent stenosis severity and plaque volume may have
acted as confounding factors in the strong association we
found between plaque enhancement and ipsilateral ischemic
stroke. Third, we found variability in how rigorously patients
with alternative causes of ischemic stroke such as car-
dioembolism or more proximal extracranial artery-to-artery
embolism were excluded from individual studies. Therefore, it
is possible that infarcts attributed to an enhancing plaque
supplying that vascular territory may have actually been
caused by another mechanism. We believe that this risk is
relatively low given our within-subjects design, in which
infarcts in the territory of enhancement were compared to
infarcts in other territories within the same patient. In other
words, if an infarct were due to cardioembolism, that infarct
should not be more likely to occur in the territory of an
Table 4. Risk of Bias Question Results
Question Answers
van der
Kolk 201114
Kim
201215
Skarpathiotakis
201316
Vakil
201317
Qiao
201418
Teng
201519
Xu
201520
Zou
201521
Was the study sample prospectively
selected to minimize the risk of selection
bias?
Yes (+) or no () + +   + + + +
Were the inclusion and exclusion criteria
adequately described?
Yes (+) or no () + + + + + + + +
Was the study’s primary objective to assess
whether enhancement was associated
with ischemic presentations?
Yes (+) or no ()  + + + + + + +
Were the investigators blinded to the
location of infarction during vessel wall
enhancement detection?
Yes (+) or no ()  + + + + + + +
Did more than 1 investigator assess for the
presence of vessel enhancement?
Yes (+) or no () + +  + + + + +
Was a measure of interreader
reproducibility for enhancement detection
reported?
Yes (+) or no ()    + +   
Did more than 1 investigator adjudicate
culprit lesion detection?
Yes (+) or no ()     +   
Were culprit and nonculprit lesions matched
in terms of vessel stenosis severity?
Yes (+) or no ()        
Note: If data not provided or not speciﬁed, recorded as no ().
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enhancing plaque than in the vascular territory of an artery
without enhancing plaque. However, we believe that future
studies should be conducted in patients with strictly deﬁned
cryptogenic stroke in whom nonstenosing intracranial
atherosclerotic plaques are present. Fourth, existing data
only provided a crude OR and not covariate-adjusted OR.
However, because most studies utilized a within-subject
design, the risk of confounding systemic vascular risk factors
should be relatively low. Fifth, as an emerging diagnostic
technique, there are relatively few studies addressing the
topic of intracranial plaque enhancement and its association
with ischemic stroke. As such, though our study showed no
statistical evidence of publication bias, this possibility should
be re-evaluated as more studies are published in this ﬁeld
since an increasing study sample size will allow for a more
valid and reliable estimate of publication bias. Sixth, there
were differences in the MRI protocols used to evaluate for
enhancing intracranial plaques, including differences in
magnet ﬁeld strength and speciﬁc pulse sequences used
by investigators. We believe that for intracranial vessel wall
MRI to be a useful tool in both clinical trial and patient care
settings, future efforts to further standardize MRI acquisition
parameters are warranted.
In summary, our systematic review and meta-analysis
suggests that MRI-detected intracranial plaque enhancement
is strongly associated with ipsilateral acute ischemic stroke.
Plaque enhancement may offer a relatively simple means to
detect a high-risk vessel wall feature that may play a
complementary role to luminal stenosis measurements in
diagnosing stroke etiology. Since conventional stroke etiology
classiﬁcation schemes attribute the cause of a stroke to large
vessel intracranial atherosclerosis only when luminal stenosis
is ≥50%, MRI for plaque enhancement may be most useful to
evaluate the etiology of strokes currently considered crypto-
genic. Future prospective studies in patients with ischemic
strokes of undetermined etiology should be undertaken in
which patients demonstrating vessel wall enhancement are
followed for recurrent ischemic events. Such studies are
necessary to test whether proven medical therapies for
secondary stroke reduction are beneﬁcial in patients with an
enhancing intracranial plaque in the vascular territory of an
acute ischemic stroke.
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Supplemental Methods: Data S1 
 
Search Methodology Details 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to 
Present - December 21, 2015 
 
1. exp Stroke/ 
2. Stroke$.tw. 
3. cerebrovascular.tw. 
4. exp Brain Ischemia/ 
5. ((brain or vascular or lacunar or venous or cerebral or isch?emi$) adj2 (accident$ or 
infarct$ or event$ or attack$)).tw. 
6. (cva or cvas).tw. 
7. exp Magnetic Resonance Imaging/ 
8. (magnetic resonance or MR or MRI or MRIs or MRA or MRDTI).tw. 
9. Contrast Media/ 
10. Imaging, Three-Dimensional/ 
11. exp Image Enhancement/ 
12. Gadolinium DTPA/ 
13. (vessel adj3 imag$).tw. 
14. (Gadolinium or Gd?DTPA or Magnograf or Magnevist or gadopentetate).tw. 
15. (contrast or enhance$ or 3?D or Dimension$).tw. 
16. Intracranial Arteriosclerosis/ 
17. Plaque, Atherosclerotic/ 
18. (LRNC or ((athero$ or steno$ or occlus$ or ulcer$ or plaque$ or intraplaque or 
h?emorrhag$ or IPH or narrow$ or obstruct$ or constrict$ or bruit$ or lipid or fibrous or 
culprit or lesion$) adj3 (intracranial or cerebr$ or brain))).tw. 
19. or/1-6 
20. or/7-8 
21. or/9-15 
22. or/16-18 
23. and/19-22 
24. (animals not (humans and animals)).sh. 
25. 23 not 24 
 
The Cochrane Library Wiley - December 21, 2015 
 
#1 MeSH descriptor: [Stroke] explode all trees 
#2 stroke  
#3 cerebrovascular  
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#4 MeSH descriptor: [Brain Ischemia] explode all trees 
#5 ((brain or vascular or lacunar or venous or cerebral or isch*emi*) near/2 
(accident* or infarct* or event* or attack*))  
#6 cva or cvas  
#7 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 
#8 magnetic resonance or MR or MRI or MRIs or MRA or MRDTI  
#9 MeSH descriptor: [Contrast Media] this term only 
#10 MeSH descriptor: [Imaging, Three-Dimensional] this term only 
#11 MeSH descriptor: [Image Enhancement] explode all trees 
#12 MeSH descriptor: [Gadolinium DTPA] this term only 
#13 vessel near/3 imag*  
#14 Gadolinium or Gd*DTPA or Magnograf or Magnevist or gadopentetate  
#15 contrast or enhance* or 3*D or Dimension*  
#16 MeSH descriptor: [Intracranial Arteriosclerosis] this term only 
#17 MeSH descriptor: [Plaque, Atherosclerotic] this term only 
#18 (LRNC or ((athero* or steno* or occlus* or ulcer* or plaque* or intraplaque or 
h*emorrhag* or IPH or narrow* or obstruct* or constrict* or bruit* or lipid or fibrous or 
culprit or lesion*) near/3 (intracranial or cerebr* or brain)))  
#19 #1 or #2 or #3 or #4 or #5 or #6  
#20 #7 or #8  
#21 #9 or #10 or #11 or #12 or #13 or #14 or #15  
#22 #16 or #17 or #18  
#23 #19 and #20 and #21 and #22 
 
Embase (Ovid) 1974 to January 31, 2014- December 21, 2015 
 
1. exp cerebrovascular accident/ 
2. Stroke$.tw. 
3. cerebrovascular.tw. 
4. exp brain ischemia/ 
5. ((brain or vascular or lacunar or venous or cerebral or isch?emi$) adj2 (accident$ or 
infarct$ or event$ or attack$)).tw. 
6. (cva or cvas).tw. 
7. exp nuclear magnetic resonance imaging/ 
8. (magnetic resonance or MR or MRI or MRIs or MRA or MRDTI).tw. 
9. exp contrast medium/ 
10. three dimensional imaging/ 
11. image enhancement/ 
12. image quality/ 
13. digital subtraction angiography/ 
14. radiography/ 
15. computer assisted tomography/ 
16. positron emission tomography/ 
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17. single photon emission computer tomography/ 
18. gadolinium pentetate/ 
19. (vessel adj3 imag$).tw. 
20. (Gadolinium or Gd?DTPA or Magnograf or Magnevist or gadopentetate).tw. 
21. (contrast or enhance$ or 3?D or Dimension$).tw. 
22. brain atherosclerosis/ 
23. atherosclerotic plaque/ 
24. (LRNC or ((athero$ or steno$ or occlus$ or ulcer$ or plaque$ or intraplaque or 
h?emorrhag$ or IPH or narrow$ or obstruct$ or constrict$ or bruit$ or lipid or fibrous or 
culprit or lesion$) adj3 (intracranial or cerebr$ or brain))).tw. 
25. or/1-6 
26. or/7-8 
27. or/9-21 
28. or/22-24 
29. and/25-28 
30. ((animal or nonhuman) not (human and (animal or nonhuman))).de. 
31. 29 not 30  
 
 
Risk of Bias Questions 
 
1. Was the study sample prospectively selected to minimize the risk of selection bias? 
 
2. Were the inclusion and exclusion criteria adequately described? 
 
3. Was the study's primary objective to assess whether enhancement was associated 
with ischemic presentations? 
 
4. Were the investigators blinded to the location of infarction during vessel wall 
enhancement detection? 
 
5. Did more than one investigator assess for the presence of vessel enhancement? 
 
6. Was a measure of interreader reproducibility for enhancement detection reported? 
 
7. Did more than one investigator adjudicated culprit lesion detection? 
 
8. Were culprit and nonculprit lesions matched in terms of vessel stenosis severity? 
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Supplemental Methods: Data S1 
 
Search Methodology Details 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to 
Present - December 21, 2015 
 
1. exp Stroke/ 
2. Stroke$.tw. 
3. cerebrovascular.tw. 
4. exp Brain Ischemia/ 
5. ((brain or vascular or lacunar or venous or cerebral or isch?emi$) adj2 (accident$ or 
infarct$ or event$ or attack$)).tw. 
6. (cva or cvas).tw. 
7. exp Magnetic Resonance Imaging/ 
8. (magnetic resonance or MR or MRI or MRIs or MRA or MRDTI).tw. 
9. Contrast Media/ 
10. Imaging, Three-Dimensional/ 
11. exp Image Enhancement/ 
12. Gadolinium DTPA/ 
13. (vessel adj3 imag$).tw. 
14. (Gadolinium or Gd?DTPA or Magnograf or Magnevist or gadopentetate).tw. 
15. (contrast or enhance$ or 3?D or Dimension$).tw. 
16. Intracranial Arteriosclerosis/ 
17. Plaque, Atherosclerotic/ 
18. (LRNC or ((athero$ or steno$ or occlus$ or ulcer$ or plaque$ or intraplaque or 
h?emorrhag$ or IPH or narrow$ or obstruct$ or constrict$ or bruit$ or lipid or fibrous or 
culprit or lesion$) adj3 (intracranial or cerebr$ or brain))).tw. 
19. or/1-6 
20. or/7-8 
21. or/9-15 
22. or/16-18 
23. and/19-22 
24. (animals not (humans and animals)).sh. 
25. 23 not 24 
 
The Cochrane Library Wiley - December 21, 2015 
 
#1 MeSH descriptor: [Stroke] explode all trees 
#2 stroke  
#3 cerebrovascular  
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#4 MeSH descriptor: [Brain Ischemia] explode all trees 
#5 ((brain or vascular or lacunar or venous or cerebral or isch*emi*) near/2 
(accident* or infarct* or event* or attack*))  
#6 cva or cvas  
#7 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 
#8 magnetic resonance or MR or MRI or MRIs or MRA or MRDTI  
#9 MeSH descriptor: [Contrast Media] this term only 
#10 MeSH descriptor: [Imaging, Three-Dimensional] this term only 
#11 MeSH descriptor: [Image Enhancement] explode all trees 
#12 MeSH descriptor: [Gadolinium DTPA] this term only 
#13 vessel near/3 imag*  
#14 Gadolinium or Gd*DTPA or Magnograf or Magnevist or gadopentetate  
#15 contrast or enhance* or 3*D or Dimension*  
#16 MeSH descriptor: [Intracranial Arteriosclerosis] this term only 
#17 MeSH descriptor: [Plaque, Atherosclerotic] this term only 
#18 (LRNC or ((athero* or steno* or occlus* or ulcer* or plaque* or intraplaque or 
h*emorrhag* or IPH or narrow* or obstruct* or constrict* or bruit* or lipid or fibrous or 
culprit or lesion*) near/3 (intracranial or cerebr* or brain)))  
#19 #1 or #2 or #3 or #4 or #5 or #6  
#20 #7 or #8  
#21 #9 or #10 or #11 or #12 or #13 or #14 or #15  
#22 #16 or #17 or #18  
#23 #19 and #20 and #21 and #22 
 
Embase (Ovid) 1974 to January 31, 2014- December 21, 2015 
 
1. exp cerebrovascular accident/ 
2. Stroke$.tw. 
3. cerebrovascular.tw. 
4. exp brain ischemia/ 
5. ((brain or vascular or lacunar or venous or cerebral or isch?emi$) adj2 (accident$ or 
infarct$ or event$ or attack$)).tw. 
6. (cva or cvas).tw. 
7. exp nuclear magnetic resonance imaging/ 
8. (magnetic resonance or MR or MRI or MRIs or MRA or MRDTI).tw. 
9. exp contrast medium/ 
10. three dimensional imaging/ 
11. image enhancement/ 
12. image quality/ 
13. digital subtraction angiography/ 
14. radiography/ 
15. computer assisted tomography/ 
16. positron emission tomography/ 
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17. single photon emission computer tomography/ 
18. gadolinium pentetate/ 
19. (vessel adj3 imag$).tw. 
20. (Gadolinium or Gd?DTPA or Magnograf or Magnevist or gadopentetate).tw. 
21. (contrast or enhance$ or 3?D or Dimension$).tw. 
22. brain atherosclerosis/ 
23. atherosclerotic plaque/ 
24. (LRNC or ((athero$ or steno$ or occlus$ or ulcer$ or plaque$ or intraplaque or 
h?emorrhag$ or IPH or narrow$ or obstruct$ or constrict$ or bruit$ or lipid or fibrous or 
culprit or lesion$) adj3 (intracranial or cerebr$ or brain))).tw. 
25. or/1-6 
26. or/7-8 
27. or/9-21 
28. or/22-24 
29. and/25-28 
30. ((animal or nonhuman) not (human and (animal or nonhuman))).de. 
31. 29 not 30  
 
 
Risk of Bias Questions 
 
1. Was the study sample prospectively selected to minimize the risk of selection bias? 
 
2. Were the inclusion and exclusion criteria adequately described? 
 
3. Was the study's primary objective to assess whether enhancement was associated 
with ischemic presentations? 
 
4. Were the investigators blinded to the location of infarction during vessel wall 
enhancement detection? 
 
5. Did more than one investigator assess for the presence of vessel enhancement? 
 
6. Was a measure of interreader reproducibility for enhancement detection reported? 
 
7. Did more than one investigator adjudicated culprit lesion detection? 
 
8. Were culprit and nonculprit lesions matched in terms of vessel stenosis severity? 
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